Clinician Genetic-Test Orders: Signed for Care, Never Used the Results

Medicare paid roughly $3.6 million on genetic-test orders signed by a clinician who certified that he would use the results for patient care, then acknowledged he never did. The criminal opinion in the telemedicine fraud appeal describes the health care fraud scheme through a physician assistant working remotely for MedCare Staffing. He earned a fee for reviewing files, including files he rejected. The approved orders carried something much more valuable downstream: a licensed clinician’s assurance that the tests belonged in someone’s medical care.

The opinion describes orders for some 607 Medicare beneficiaries, only about 20 of whom the clinician had spoken with. That gap matters to anyone who knows how the patient information reached the reviewer, what the forms already said and what happened after the signature.

How the Pre-Populated Order Moved

The patients and proposed tests reached the clinician through a workflow already arranged by other businesses. In its account of the criminal case, the court identifies MedCare Staffing, also known as Provider Partners or Telehealth Solutions, as the telehealth company supplying the files. Helix and Whitewater were corporate clients. The physician assistant initially reviewed durable medical equipment files before the clients expanded into genetic testing.

The criminal indictment describes the electronic handoff. It alleged that the clinician received pre-populated, unsigned laboratory requisitions, medical records and Medicare beneficiary information through the staffing company and its clients. Alerts told him files were ready. Email and document-sharing platforms gave him access to review and electronically sign them. Diagnostic laboratories then received the orders and submitted claims to Medicare.

The later court opinion describes training in October 2018 on genetic-test criteria, laboratory requisitions, letters of medical necessity and cover letters transmitting results. The clinician was initially told to call beneficiaries to confirm they wanted testing. In December 2018, an operations manager told him his responsibility was “chart review and signature.” Calls were needed only if he found a discrepancy, the manager said, because the company had medical assistants and registered nurses to call patients.

That instruction narrowed the work without narrowing what the signed forms represented. The forms still said the beneficiaries were his patients, the tests were medically necessary and he would use the results in their care.

Telehealth can divide healthcare staffing, platform operations, clinical work and billing among different businesses. Here those divisions are visible in the transaction itself: clients supplied beneficiary material, the staffing company delivered it, the clinician signed and laboratories billed. An insider who knows one part of that sequence may be able to explain a representation that someone farther down the chain simply accepted.

What Did the Signed Genetic-Test Order Certify?

The signed order represented a treating relationship, medical necessity and an intention to use the results for patient care. The indictment also alleged that the clinician certified the patient records as true, accurate and complete. Those were statements about work and care, not just permission for a laboratory to run a test.

The indictment described cancer genomic testing as looking for mutations associated with a higher risk of developing certain cancers. Pharmacogenetic testing identifies gene variants affecting how a person processes medications, potentially informing drug choice and dosage. The value of either result depended on what a clinician did with it.

The training described in the opinion reduced medical necessity to broad criteria. A personal or family history of cancer satisfied the training’s criteria for cancer testing. Taking multiple medications with a risk of adverse drug events, or reporting side effects, satisfied its criteria for pharmacogenetic testing.

At the criminal trial, the government’s Medicare expert testified that coverage required a treating physician who would use the results in the beneficiary’s treatment. The expert also said Medicare did not cover tests ordered through an asynchronous encounter, where provider and patient never interact in real time. The clinician acknowledged that he did not use the results.

The paperwork described care continuing after the laboratory finished. His account stopped at the order. In a separate civil settlement’s admitted facts, a physician who approved orders through MySpecialistMD likewise acknowledged never using the test results for care.

The Clinician Was Paid for Rejected Reviews

The genetic-testing clinician was paid for rejected reviews as well as approvals. The court opinion states the fee as $12 to $15 per reviewed file, with roughly $17,628 earned in total. He never personally billed Medicare.

The signed requisitions show which reviews became orders. The laboratory claims show what those orders became when someone else sought payment.

The criminal case focused on the representations he signed. The fee alone leaves out the clinical promises that made the approved order usable downstream.

What the Compliance Assurances Actually Addressed

The compliance letter described in the criminal opinion did not address Medicare’s coverage requirements. It addressed Georgia law and federal restrictions on kickbacks and self-referrals. The clinician had never seen it. Its conclusions rested on untested assumptions that providers would follow state telemedicine requirements and generate genuine patient medical records.

The same opinion describes a client owner’s instructions to avoid ordering too many tests at once to keep from being “flagged.” He called the approval process “plug and play” and told staff to avoid “no-no words” such as “free” and “Medicare.” These instructions concerned getting orders through, not using the results to treat a patient.

The clinician testified that he trusted the company’s leadership and believed the operation was lawful. Yet the company’s assurances did not match his own account of the work: he signed forms promising to use the results and acknowledged that he never did. Medicare paid for tests that the ordering clinician never used for care.

The Laboratories’ Claims Followed the Clinician’s Orders

The court opinion connects the approved orders to more than 14,600 genetic tests and over $10 million in laboratory claims.

That is why this case matters beyond the person submitting a bill. The clinician supplied the signed representations that accompanied the orders. The laboratories submitted the claims, and Medicare supplied the money. The central contradiction sat upstream of billing: the clinician said he would use results for care and acknowledged that he did not.

For a clinician or operations employee, the December instruction and the language left on the forms may explain that contradiction. For a laboratory employee, the order and the claim may show where the certification entered the payment process. We work with insiders to connect those particular records to what happened in practice, including what the signer knew and what happened to the results. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Happened After the Signature

If you know who supplied the patient files, what reviewers were told or where the results went, speak with our whistleblower experts about the genetic-test orders you saw. We build the case with you and bring in telehealth fraud whistleblower lawyers who understand clinical certifications and downstream laboratory claims. We stay beside you as your knowledge of the workflow becomes the evidence behind the case.